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latter group were more likely to use prescribed opioid substitution therapy, often alongside diverted
pharmaceutical opioids. Socio-demographic and clinical profiles did not vary according to high dose opioid,
alcohol and benzodiazepine use, and there was no association with harms. Conclusions Same-day use of
opioids with benzodiazepines/alcohol, and high dose combinations, are common amongst people who
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Abstract
Objective: The aims were to determine: i) quantity and frequency of same-day use of opioids
with benzodiazepines and/or alcohol amongst people who regularly tamper with
pharmaceutical opioids; and iii) socio-demographic, mental health, harms and treatment
profile associated with same-day use of high doses.
Method: The cohort (n=437) completed a retrospective 7-day diary detailing opioid,
benzodiazepine, and alcohol intake. Oral morphine equivalent (OME) units and diazepam
equivalent units (DEU) were calculated, with >200mg OME, >40mg DEU and >4 standard
alcoholic drinks (each 10g alcohol) considered a “high dose”.
Results: One-half (47%) exclusively consumed opioids without benzodiazepines/alcohol;
26% had days of opioid use with and without benzodiazepines/alcohol; and 26% always used
opioids and benzodiazepines/alcohol. Same-day use of opioids with benzodiazepines/alcohol
typically occurred on 1-3 days in the past week. Six in ten (61%) participants reported high
dose opioid use on at least one day; one in five (20%) reported high dose opioid and high
dose benzodiazepine/alcohol use on at least one day. The latter group were more likely to use
prescribed opioid substitution therapy, often alongside diverted pharmaceutical opioids.
Socio-demographic and clinical profiles did not vary according to high dose opioid, alcohol
and benzodiazepine use, and there was no association with harms.
Conclusions: Same-day use of opioids with benzodiazepines/alcohol, and high dose
combinations, are common amongst people who tamper with pharmaceutical opioids.
Assessment of concomitant benzodiazepine/alcohol use during opioid therapy,
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implementation of real-time prescription monitoring systems, and research to clarify upper
safe limits for polydrug depressant use, are potential implications.
Keywords: opioid; benzodiazepine; alcohol; concurrent use; polydrug abuse; overdose
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1. Introduction
There has been an increase in opioid prescriptions, partly attributable to greater chronic noncancer pain (CNCP) prevalence and a greater number of opioids registered for CNCP
treatment (Berterame et al., 2016; Karanges et al., 2016). Increased pharmaceutical
availability has seen greater prevalence of extra-medical use and tampering (i.e.,
manipulating a dosage form to change its drug delivery in a way not specified by the
manufacturer, and may include dissolving, crushing, chewing, snorting and injecting) (Katz
et al., 2011; Katz et al., 2007), which in turn has led to greater rates of opioid-related harms
(Hall et al., 2008; Laxmaiah Manchikanti et al., 2012).
Use of other central nervous system depressants, such as benzodiazepines and alcohol, with
opioids may have an interactive or synergistic effect, increasing the risk of acute harms such
as overdose (Warner-Smith et al., 2001; White and Irvine, 1999). An increasing proportion of
unintentional overdoses have been observed involving the use of benzodiazepines, alcohol
and other depressant drugs with opioids (Calcaterra et al., 2013; Jones et al., 2013), with
death primarily attributed to respiratory depression (Gudin et al., 2013). As tolerance to the
depressant effects of opioids is slower than tolerance to euphoric effects, consumers with a
long history of opioid use are still often unknowingly at risk, although the underlying
pathophysiology is complex and poorly understood (White and Irvine, 1999).
In addition, combined depressant use may contribute to increased sedation, greater motor
impairment (e.g., falls or injuries) and enhanced abuse liability of these substances.
Benzodiazepine or alcohol use enhances the euphoric effects of opioid analgesics (Chen et
al., 2011; Lintzeris et al., 2007; Zacny and Gutierrez, 2011) and acute alcohol coadministration may increase maximum plasma concentrations and reduce time to maximum
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concentration for long-acting opioids (Fiske et al., 2012; Johnson et al., 2012; Sathyan et al.,
2008) .
Few studies have conducted in-depth investigation of concurrent use (specifically, same-day
use) of opioids and benzodiazepines and/or alcohol among people who use opioids (e.g.,
Brands et al., 2008; Cropsey et al., 2015; Fleming et al., 2007; Lavie et al., 2009; Nielsen et
al., 2007; Saunders et al., 2012). This is particularly the case for people regularly engaging in
extra-medical pharmaceutical opioid use, a group at greater risk of opioid-related harms and
among whom use of a range of substances is prevalent (Becker et al., 2008; Jones, 2013). As
such, the aims of this study were to apply a novel methodology, a retrospective self-report
daily drug diary, to determine:
1. Frequency of same-day opioid use with benzodiazepines/alcohol, and typical
quantities consumed, by people who regularly tamper with prescription opioids; and
2. Demographic, mental/physical health, drug use, harms and treatment profile correlates
of same-day use of opioids, benzodiazepines, and alcohol at high doses.
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2. Material and Methods
2.1 Participants and Procedure
We used data from the National Opioid Medication Abuse Deterrence (NOMAD) study, a
prospective cohort (n=606) of people who reported regular extra-medical use and tampering
with pharmaceutical opioids. Participants were recruited from metropolitan areas of New
South Wales, Tasmania, and South Australia. Inclusion criteria required that participants: i)
were aged ≥ 18, ii) reported monthly or more frequent extra-medical pharmaceutical opioid
use in the preceding six months, and iii) reported injecting, snorting, chewing or smoking
pharmaceutical opioids on a monthly or more frequent basis in the preceding six months.
Exclusion criteria comprised use of pharmaceutical opioids only in accordance with
professional medical advice, or residing outside the metropolitan area/in prison for a month
or longer in the preceding six months. Further details of the study are available from
Degenhardt et al. (2015). The study was approved by the Human Research Ethics Committee
of the University of New South Wales.

The current study utilised data from the third interview (‘Wave 3’) in April-June, 2015
(n=499, 82% of the original cohort; 90% of those not in residential treatment or prison at the
time of interview, and still alive at the time of follow-up). Only data collected in the 60minute computer-assisted interview from participants who completed the seven-day
retrospective drug diary component (n=5 excluded) and who reported at least one day of
opioid use (n=57 excluded) were included (final sample n=437; see Supplementary Table 1
for comparison of final sample versus those excluded).

2.2

Key Measures

2.2.1 Drug Diary
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Using a Timeline Follow-back approach (Sobell and Sobell, 1996), participants were asked to
identify any alcohol, illicit drugs, and prescription medicines (including those not directly
prescribed to them) which they had consumed in the past seven days. Participants reported
intake on each day from the day prior to interview (Day 1) to Day 7. The approximate time of
waking and sleeping (and time of drug consumption where reported) were obtained to
facilitate recall. Participants reported the type/brand, quantity, unit (e.g., four 40mg morphine
tablets), route of administration, and source (e.g., own prescription, bought from dealer).
Prompt cards with photographs of medications (full array of tablet sizes) were used to help
identify the correct medicine/formulation.

2.2.2 Sample Characteristics and Mental/Physical Health
In addition to standard socio-demographic items, depression and generalised anxiety disorder
were measured using the PHQ-9 and GAD-7 modules of the Patient Health Questionnaire
(Kroenke et al., 2010). Likely presence of moderate to severe depression was defined as a
PHQ-9 score of ≥ 10 (Kroenke et al., 2001); and likely symptoms of moderate to severe
anxiety were defined as a GAD-7 score of ≥ 10 (Spitzer et al., 2006). Participants were also
asked the first item of the Brief Pain Inventory; specifically, whether they had experienced
pain (non-everyday) in the past month (Tan et al., 2004).

2.2.3 Drug Use and Behaviours
The Composite International Diagnostic Interview (World Health Organisation, 2001)
assessed past-12 month pharmaceutical opioid use disorder based on the International
Classification of Diseases (ICD-10) criteria. Participants reported whether they had used
heroin, cannabis and methamphetamine in the past month. A short form of the Alcohol Use
Disorders Identification Test (AUDIT-C) was included; a cut-off score of 5 was used to
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indicate alcohol-related problems (Bush et al., 1998). The Severity of Dependence Scale
(SDS) was used to assess severity of benzodiazepine dependence; a cut-off score of 7 was
used to indicate possible dependence (Cuevas et al., 2000).

2.2.4 Harms and Treatment
Participants were asked about frequency of injecting any drug in the past month (with
subsequent coding of binary ‘any injection’ and ‘daily injection’ variable), and whether they
had overdosed in the past 12 months. Participants also reported past month engagement in
opioid substitution treatment (OST) and past 12 month hospital and general practitioner visits
(for any health-related reason).

2.3 Data Analysis
2.3.1 Calculating Oral Morphine Equivalent (OME) Units and Diazepam Equivalent Units
(DEU)
Opioid doses reported in the daily diary were converted into oral morphine equivalent (OME)
units using conversion factors outlined by Nielsen et al. (2015). This conversion allows for
comparison of opioid consumption across participants using different opioids based on the
concept of equianalgesic dosing, where different doses of different opioids have similar
analgesic effects. An OME unit is measured as being equivalent to 1mg of orallyadministered morphine. The conversion factors have been created such that the OME
consumed on a particular day is calculated by multiplying the quantity of the particular opioid
by the appropriate factor accounting for route of administration; for example, a participant
who injected 80mg of oxycodone on one day has consumed 240mg OME (80mg multiplied
by conversion unit for oxycodone injection of 3).
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A similar process was undertaken to calculate diazepam equivalent units (DEU) (National
Prescribing Service, 1990; The Royal Australian College of General Practitioners, 2015;
Therapeutic Guidelines Limited, 2013). One DEU is equivalent to 1mg of orallyadministered diazepam. The number of DEU consumed on a particular day was calculated by
multiplying the quantity of the particular benzodiazepine by the appropriate factor (e.g., oral
0.5mg alprazolam is multiplied by conversion unit of 10). Conversion rates for non-oral route
of administration were not used although they would be anticipated to be higher (only 8
participants reported injecting benzodiazepines in the past month).

2.3.2 Statistical Analyses
SPSS Statistics Version 22 (IBM, Somers, NY) was used to calculate descriptive statistics,
including percentages for categorical outcomes and median and interquartile range (M, IQR)
for continuous outcomes. The percentage of participants who reported each opioid
consumption practice (opioid only, same-day opioid and benzodiazepine, same-day opioid
and alcohol, and same-day opioid, benzodiazepine and alcohol use) across the seven days;
percentage of participants reporting 0-7 days of each consumption practice; and the
proportion of opioid use days where each of these consumption practices were reported for
daily opioid users, were calculated.

Median days of use and intake were reported for each consumption practice, as well as the
percentage of participants exceeding a high dose threshold on any day of use of that
consumption practice. The cut-off for a high opioid dose was >200mg OME based on
previously determined cut-offs of opioid dose associated with high overdose risk
(Manchikanti et al., 2012). The cut-off for a high benzodiazepine dose was >40 mg DEU
reflecting the upper maximum daily dose of oral diazepam licensed in Australia (National
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Prescribing Service, March 2016). In previous laboratory studies, 40mg oral diazepam (but
not 10 or 20mg) was associated with features of respiratory depression in combination with
routine methadone doses in a proportion of patients in methadone treatment (Lintzeris et al.,
2006; Lintzeris et al., 2007). The high alcohol dose cut-off was >4 standard drinks (1
standard drink = 10g) in accordance with Australian National Health and Medical Research
Council guidelines to minimise risk of acute harms (National Health and Medical Research
Council, 2009).

Multinomial logistic regression analyses were conducted to identify the socio-demographic,
mental and physical health, drug use, harms and treatment characteristics associated with: i)
opioid use ≤200mg OME on every day of use, ii) opioid use >200mg OME on at least one
day of opioid use [referent category], and iii) opioid use >200 mg and same-day use of
benzodiazepine >40 mg and/or alcohol intake >4 standard drinks on at least one day. Relative
risk ratios (RRR) are reported.

Concern has been expressed regarding conversion of oral methadone to oral morphine
equivalents using a linear dose conversion (Anderson et al., 2001), as large methadone doses
(e.g. >80mg) translates to very high OME (e.g. >300mg). Further, there is evidence of
reduced mortality risk with long-term methadone maintenance dosing (Cornish et al., 2010).
Consequently, sensitivity analyses were also run for frequency and intake estimates, and
correlates of high dose intake, excluding those participants who had used only prescribed
opioid substitution therapy (OST) only (including those who reported prescribed OST and
prescribed pharmaceutical opioid use) due to concerns that conversion rates for methadone
may be artificially inflating OME dose.
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3.

Results

3.1 Sample Characteristics
At Wave 3, the majority of the sample were male (66%), with a median age of 43 (IQR 3649). Half (57%) reported income <AUD$400/week. Over one-tenth were currently homeless
(14%), and 63% reported ever being incarcerated. Based on data provided in the interview,
60% (n=263) had received opioid substitution treatment (OST); 36% had used their own
prescribed benzodiazepines; 59% had used any benzodiazepines (all sources); and 48% had
used alcohol, in the past month. The majority of the sample (85%) had injected a drug in the
past month (34% daily injection), and two-thirds (67%) met ICD-10 criteria for an opioid use
disorder in the preceding 12 months.

3.2 Frequency and quantity of same-day use
The majority of participants (70%) reported opioid use every day in the preceding week; 9%
reported 6 days of opioid use, 10% reported 4-5 days, 7% reported 2-3 days, and only 5%
reported one day of opioid use (Figure 1). Indeed, on a given day, a maximum of 17%
reported no opioid use, 61% opioid only use, 21% opioid and benzodiazepine use, 10%
opioid and alcohol use, and 6% opioid, benzodiazepine and alcohol use (Supplementary
Figure 1).

One-half of the sample (47%) consumed exclusively only opioids only throughout the week;
one quarter (26%) had day(s) where they consumed opioids alone and day(s) where they
consumed opioids and benzodiazpines and/or alcohol; and 26% reported that all days of
opioid use also involved benzodiazepines and/or alcohol. Of note, 38% of the latter group
alternated between same-day use of opioids and benzodiazepines, same-day use of opioids
and alcohol, and/or same-day use of opioids, benzodiazepines and alcohol.
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Examination of the number of days participants engaged in each opioid consumption
behaviour showed that 34% of the sample reported one or more days of same-day opioid and
benzodiazepine use (8% daily use); 19% reported one or more days of same-day opioid and
alcohol use (3% daily use); and 11% reported one or more days of same-day opioid,
benzodiazepine and alcohol use (1% daily use) (Figure 1).

***Figure 1 approximately here***

Focusing specifically on the 70% (n=306) of participants who reported using opioids every
day in the past week, same-day use of opioids with benzodiazepines and/or alcohol was
infrequent (Supplementary Figure 2). One-third (37%) reported reported using opioids and
benzodiazepines on the same day (25% of these reported only one day of such use), 20%
reported using opioids and alcohol on the same day (42% of these reported only one day of
such use), and 11% reported using opioids, benzodiazepines and alcohol the same day (50%
of these reported only one day of such use).
Median OME when consuming opioids only (i.e., without benzodiazepines or alcohol on the
same day) was 380mg (Table 1); 400mg OME when using opioids and benzodiazepines;
410mg OME when using opioid, benzodiazepine and alcohol use; and 353mg OME when
using opioids and alcohol. Considerable variability in typical intake was evident given the
interquartile range for estimates (Table 1). When considering dose on any day of opioid use
(i.e., regardless of whether benzodiazepine or alcohol ingested), 80% of the sample reported
at least one day where they exceeded 200mg OME.
***Table 1 approximately here***
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Median benzodiazepine dose was similar for those reporting same-day opioid and
benzodiazepine use with and without alcohol (both 20mg DEU), with 30% and 26%
exceeding 40mg DEU on at least one day, respectively. Median alcohol intake was higher
when participants reported same-day opioid and alcohol use versus same day opioid,
benzodiazepine and alcohol use (4.6 versus 3.3 standard drinks), with 61% and 53%
exceeding four standard alcoholic drinks on at least one day, respectively (Table 1).

3.3 Socio-Demographic, Mental and Physical Health, Drug Use, Harms and Treatment
Characteristics of Each Group
Participants were classified into:
1. ‘High Dose Opioid Group’: reported using >200mg OME on at least one day (but no
same-day use of >40mg DEU and/or > four standard alcoholic drinks; 61%, n=267);
2. ‘Lower Dose Opioid Group’: reported only using ≤200mg OME (20%, n=89); and
3. ‘High Dose Combined Depressant Group’: one-fifth (20%, n=81) reported:
a. ≥1 day of using >200mg OME and >40mg DEU (8%; n=33);
b. ≥1 day of using >200mg OME and >4 standard alcoholic drinks (10%, n=42);
c. Both 3A and 3B on separate days (1%, n=3); and
d. ≥1 day of using >200mg OME, >40mg DEU and >4 standard alcoholic drinks
(1%, n=3).
Breakdown of these three groups according to use of prescribed, non-prescribed and illicit
opioids (Table 2) showed that the majority (53%) of the ‘Lower Dose Opioid Group’ had
consumed exclusively non-prescribed or illicit opioids in the preceding seven days, while
only one-fifth of the ‘High Dose Opioid Group’ (22%) and the ‘High Dose Combined
Depressant Group’ (17%) reported such use. Four-fifths of the ‘High Dose Opioid Group’
(78%) and the ‘High Dose Combined Depressant Group’ (83%) had received pharmaceutical
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opioids and/or OST from a medical professional, with 38% and 35% using exclusively
prescribed opioids in the preceding week, respectively.

The ‘High Dose Combined Depressant Group’ had a greater RRR of depression than the
‘High Dose Opioid Group’ (Table 3). There were similar rates of use of illicit drugs, daily
injection and overdose across the groups, although low numbers should be noted in the latter
case. The ‘High Dose Combined Depressant Group’ had a greater RRR of past month
cannabis use and prescribed benzodiazepine use relative to the ‘High Dose Opioid Group’,
with 48% of the former group reporting prescribed benzodiazepine use.

3.4 Sensitivity Analyses
Sensitivity analyses excluding those who used prescribed OST only (final subsample n=301)
showed that whilst median OME decreased, the percentage of participants who reported
exceeding the opioid high dose threshold for each opioid consumption practice was similar
relative to the full sample (Supplementary Table 2). Median DEU and standard drink intake,
and the percentage who exceeded high dose thresholds for these substances when also using
opioids, were similar in the full sample and subsample. Approximately two-thirds of the
‘High Dose Opioid Group’ (66%, n=175) and the ‘High Dose Combined Depressant Group’
(69%, n=56), and four-fifths (79%, n=70) of the ‘Lower Dose Opioid Group’, were retained
in the subsample, suggesting that removal of those who used prescribed OST only did not
result in a decrement in the high opioid dose groups only (Supplementary Table 3).
Identification of correlates of group was hampered by low statistical power, although there
was a trend towards higher rates of depression amongst the ‘High Dose Combined
Depressant Group’ relative to ‘High Dose Opioid Group’, as per analysis of the full sample.
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4.

Discussion

This study is unique relative to previous research examining opioid, benzodiazepine and
alcohol use (e.g., Brands et al., 2008; Cropsey et al., 2015; Fleming et al., 2007; Lavie et al.,
2009; Nielsen et al., 2007; Saunders et al., 2012) given the depth of data on frequency and
quantity of use. Over two-thirds of the current sample had used opioids every day in the
preceding week, and over half reported at least one day where they used opioids and
benzodiazepines/alcohol. The majority of participants engaged in this consumption practice
infrequently, and only one-tenth reported same-day use of all three. Whilst one-fifth of the
sample consistently used ≤200mg OME (‘Lower Dose Opioid Group’), three-fifths used
>200mg OME on one or more days (‘High Dose Opioid Group’) and one-fifth used >200mg
OME plus >40mg DEU and/or >4 standard alcoholic drinks on at least one day (‘High Dose
Combined Depressant Group’). Opioid intake for the ‘Lower Dose Opioid Group’ was
primarily derived from non-prescribed or illicit opioids use, whereas half of the ‘High Dose
Combined Depressant Group’ had used both prescribed pharmaceutical opioids/OST and
non-prescribed/illicit opioids in the preceding week. However, rates of exceeding the high
dose threshold were maintained when excluding participants who used prescribed OST only.
There were few statistically-significant group differences in demographics, health, substance
use, harms and treatment, with the exception that the ‘High Dose Combined Depressant
Group’ had greater risk of depression (consistent with findings of Rooney et al., 1999; Ross
and Darke, 2000) and past month cannabis use.

The finding that same-day use of opioids with benzodiazepines and/or alcohol is common
amongst the sample fits with prior research (Fleming et al., 2007; Saunders et al., 2012), with
the exception of lower rates of concurrent use amongst criminal justice samples (Cropsey et
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al., 2015). However, it is the general infrequency of this behaviour, and evidence of
variability in use of benzodiazepines and/or alcohol alongside opioids from day to day, that is
of concern in regards to adverse events. The elevated risk of overdose from use of
benzodiazepines, independently and with other depressants, is well-established (Buykx et al.,
2010; Darke et al., 1996). Repeated administration of psychoactive substances results in
tolerance, whereby the effects of a substance are reduced due to neuroadaptation. However,
in the absence of regular use there may be less tolerance to the sedating effects of
benzodiazepines/alcohol, resulting in a greater risk of respiratory depression and subsequent
overdose (Jones et al., 2012; Lintzeris and Nielsen, 2010). In this study, greater risk of nonfatal overdose was not evident amongst the group reporting ingesting high opioid doses with
same-day high benzodiazepine/alcohol intake. However, this sample comprised individuals
who are generally ingesting high opioid doses (>200mg OME) on a daily basis, and caution
should be applied in interpreting these findings due to low statistical power (i.e., smaller
group sizes coupled with low rate of overdose).

4.1 Implications
Prescribing guidelines recommend medical supervision in opioid therapy and OST;
concurrent prescribing of benzodiazepines is generally not recommended or, where
unavoidable, used only under certain conditions (e.g., lower doses of methadone or when
prescribing buprenorphine; Manchikanti et al., 2012; Nielsen et al., 2007). Concomitant
consumption of alcohol with opioids is not advised (Gowing et al., 2014; Health et al., 2009).
However, four-fifths of the ‘High Dose Combined Depressant Group’ had used
pharmaceutical opioids and/or OST prescribed by a medical professional in the past week,
and half had received prescribed benzodiazepines in the preceding month. Consequently, it
appears that the majority of those at risk of harm are already under supervision of a
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prescribing health professional. It is not clear if the OST prescriber would be aware of
benzodiazepines being prescribed by other prescribers, or alcohol consumption unless
specifically screened for. Implementation of real-time prescription monitoring across states
and territories in Australia may rectify this situation to some extent (Ogeil et al., 2016).
However, it will not address the risk associated with concomitant benzodiazepine use due to
the exclusion of most benzodiazepines from planned monitoring programs in Australia
(Nielsen and Bruno, 2014). Nor will it identify use of diverted pharmaceutical opioids, which
represents the majority of non-prescribed pharmaceutical opioid use in this group. Notably,
half of the high dose opioid groups were using opioids sourced outside the bounds of a
doctor’s prescription. This raises important questions about how unsanctioned medication use
is best detected above and beyond comprehensive assessment by prescribers, and the role of
regular urine drug screening in the prescribing of opioids (both in the context of chronic noncancer pain and OST) (Ross et al., 2007; Starrels et al., 2010). Further, the role of harm
reduction services in education may also be critical as those people using unsanctioned
medications may be unlikely to discuss the risks with health professionals for fear of
disclosure adversely affecting their supply. Take-home naloxone provision where there is risk
of combined depressant use might be an important precautionary action in such cases.

The three groups were not distinguishable on the basis of screening measures for opioid
dependence, benzodiazepine dependence, and hazardous alcohol use. This suggests that these
substance-specific screening questionnaires may not discriminate those at risk of adverse
outcomes for using concomitant opioids with other CNS depressants. The three groups were
also not distinguishable on the basis of past year overdose and other harms, potentially due to
low rates of these outcomes. These findings reinforce the need to extend beyond screening
for dependence or aberrant medication-related behaviours to explicitly gathering information
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regarding concomitant benzodiazepine and alcohol use when prescribing opioid therapy or
OST, with possible implementation of those measures mentioned above (e.g., urine drug
testing, provision of naloxone) to increase the possibility that hazardous depressant use is
detected and harms are prevented where self-report is not accurate. Comprehensive
assessment of overdose risk factors, such as concomitant depressant use, via both self-report
and objective measures is critical to minimise behaviours and ensure harm reduction
measures are considered.

Review of guidelines for this manuscript yielded various maximum recommended opioid
doses to reduce overdose risk (typically ranging between 40-200mg OME) (Dowell et al.,
2016; Manchikanti et al., 2012). Guidelines as to the maximum benzodiazepine and alcohol
intake concomitant with opioids were not available, and recommendations for
benzodiazepine prescribing typically focused on maximum dose for therapeutic purpose as
opposed to the threshold for adverse outcomes. A lack of consensus or even specification of
high dose thresholds most likely reflects a lack of understanding and scarcity of data
regarding polydrug interactions. Further to this, the current analyses presume a set cut-off for
each individual. Whilst not possible to take this into consideration in the current study, each
individual’s risk threshold will vary according to their history of use of the substances, as
well as individual factors such as physical health and changes in tolerance. Again, these
findings highlight the importance of a comprehensive assessment of risk factors for adverse
outcomes when prescribing opioids.

4.2 Limitations
While the methodology provided considerable depth of detail regarding same-day patterns of
use, it is important to note that this sample does not generalise to all opioid consumers.
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Participants entered the study on the basis of extra-medical use and tampering with
pharmaceutical opioids, and over half were receiving OST, meaning that this sample could
theoretically already be identified as high risk. This conclusion is reinforced by the majority
exceeding the high opioid dose (from heroin, pharmaceutical opioids and/or OST intake) on
any day in the preceding week.

Data were retrospectively self-reported however participants were provided in-depth
instruction with multiple prompts; there were no negative consequences for disclosing
behaviours; interviewers were trained; and previous research points to validity and reliability
of self-report in assessing drug use (Darke, 1998), particularly when using a Timeline
Follow-back approach (Hjorthøj et al., 2012). It should also be noted that a conservative
approach to data collection was undertaken, whereby failure to recall use that day was
marked as abstinent.

Published equivalence tables taking into account route of administration were used for
conversion to standard units (OME and DEU). Whilst issues around conversion of methadone
dose to OME have been flagged, caution should also be applied when considering conversion
ratios in general, being influenced by individual factors (e.g., opioid exposure,
bioavailability, and presence of other drugs), particularly chronic consumption (Patanwala et
al., 2007; Pereira et al., 2001). Conversion for opioid dose took into account oral versus
intravenous administration, however these analyses also do not account for the role of route
of administration and associated overdose risk (Brugal et al., 2002; Degenhardt et al., 2011).

4.3 Conclusion
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This cohort comprised a diverse group of participants who report regular use of high doses of
a range of prescribed, diverted and illicit opioids. Same-day use of opioids with
benzodiazepines and/or alcohol was common, but did not typically occur daily, and there
were different patterns of concomitant use of alcohol and/or benzodiazepines (e.g., use of
opioids and benzodiazepines on one day, and opioids and alcohol on the next). This type of
use poses high risk for adverse outcomes due to relatively lower tolerance, although
participants in the current study reporting high dose same-day depressant use were not
distinguishable from those using high opioid doses only in regards to rate of overdose. Most
of those reporting same-day high opioids doses with high benzodiazepine/alcohol doses used
opioids dispensed by a medical, speaking to the importance of explicit assessment of
concomitant depressant use when prescribing and monitoring treatment, potentially faciliated
by urine drug sceen and real-time prescription monitoring. Further, research assessing safety
thresholds for concomitant depressant use is essential given a lack of consensus regarding, or
even data to inform, upper safe limits for each drug.
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Figure 1. Percentage of participants according to number of days in the past week (0-7 days) self-reported opioid use, with and without
benzodiazepine and alcohol use.

Table 1
Frequency and Quantity of Opioid Use, with and without Benzodiazepines and Alcohol

Same-Day
Consumption
Practice

Total sample
reporting at
least one day
of behaviour
%(n)

Median
Days of
Use (IQR)

Median mg
OME/Day
(IQR)

% >200mg
OME/Day
(on any day of
use)

Median mg
DEU/Day (IQR)

% >40mg
DEU/Day (any
day)

Median
Standard
Drinks/Day
(IQR)

% >4 Standard
Drinks/Day
(any day)

Any opioid use
(regardless of
concurrent use)

100 (437)

7 (6-7)

390 (196-621)

80

-

-

-

-

Opioid only

79 (343)

6 (4-7)

380 (199-621)

79

-

-

-

-

Opioid +
Benzodiazepine

34 (149)

3 (1-6)

400 (180-595)

79

20 (10-34)

26

-

-

Opioid + Alcohol

19 (84)

2 (1-4.75)

353 (182-559)

69

-

-

4.6 (3.0-9.8)

61

Opioid +
Benzodiazepine +
Alcohol

11 (47)

1 (1-3)

410 (270-616)

77

20 (10-63)

30

3.3 (2.0-7.0)

53

Note. All participants report at least one day of opioid use; possible range for days of use is 1-7. Note that the any opioid use results represent
findings for any days on which opioids are used, regardless of whether benzodiazepine or alcohol use is present or absent. The median dose for
the remaining outcomes (opioid only, opioid + benzodiazepine, opioid + alcohol, opioid +benzodiazepine + alcohol) is only calculated for days
of use for the specific behaviour (e.g., median OME and DEU across days having opioids + benzodiazepines); and the percentage exceeding the
cut-off (200mg OME, 40mg DEU, 4 standard alcoholic drinks) is calculated based on dose on any day where that consumption practice is
reported (‘any day’). OME: oral morphine equivalent units; DEU: oral diazepam equivalent units; IQR: interquartile range.

Table 2
Percentage Reporting Prescribed, Non-Prescribed and Illicit Opioid Use According to Group

Total Sample
n=437

A.

B.

High Dose
Opioid Group

Lower Dose
Opioid Group

n=267

n=89

C.
High Dose Opioid and
Benzodiazepine/Alcohol
Group

n=81
% prescribed PO only
7
3
21
4
% prescribed OST only
29
32
20
30
% prescribed PO and OST
2
3
1
1
use only
% prescribed PO and
8
9
3
9
diverted/illicit
% prescribed OST and
26
31
1
35
diverted/illicit
% prescribed PO and
prescribed OST and non2
1
5
prescribed/illicit
% non-prescribed/illicit only
27
22
53
17
Note. Diverted/illicit refers to any use of non-prescribed pharmaceutical opioids, non-prescribed OST, and/or heroin. PO: pharmaceutical opioid (morphine, oxycodone,
tramadol, physeptone, Norspan, fentanyl, codeine); OST: opioid substitution treatment (methadone syrup, Subutex, Suboxone).

Table 3
Correlates of High Dose Opioid Use, With and Without High Dose Alcohol and/or Benzodiazepine Concurrent Use (N=437)
C.
Total Sample

Total Sample

N

% (95%CI)

A.

B.

High Dose
Opioid Group

Lower Dose
Opioid Group

N=267

N=89

% (95%CI)

% (95%CI)

High Dose
Combined
Depressant
Group

B vs A (ref)

C vs A (ref)

RRR (95%CI)

RRR (95%CI)

N=81
% (95%CI)

Demographics
Age (M, IQR)#

436

43 (36-49)

43 (35-49)

42 (37-48)

42 (36-49)

1.01 (0.98-1.03)

1.01 (0.98-1.03)

Male

437

66

66

67

67

1.07 (0.64-1.78)

1.03 (0.61-1.75)

Unemployed (B)

437

82

82

79

83

0.79 (0.43-1.43)

1.02 (0.53-1.97)

Education <year 10 (B)

436

27

26

27

30

1.05 (0.61-1.81)

1.20 (0.69-2.08)

Income <$400 per week

434

48

47

50

53

1.15 (0.71-1.86)

0.79 (0.48-1.30)

Homeless/no fixed abode

436

14

13

17

15

1.38 (0.71-2.68)

1.27 (0.77-2.09)

Lifetime prison history

437

63

62

58

70

0.87 (0.53-1.42)

1.47 (0.86-2.51)

435

57

55

60

58

1.19 (0.73-1.94)

1.10 (0.66-1.82)

Mental/Physical Health
Pain (non-everyday) past
month

Moderate/severe depression
(≥10 PHQ-9)

420

48

45

47

58

1.09 (0.66-1.78)

1.71 (1.03-2.84)*

Moderate/severe anxiety (≥10
GAD-7)

417

33

33

23

41

0.61 (0.34-1.09)

1.41 (0.84-2.37)

ICD-10 opioid use disorder
(past 12 months)

432

67

65

72

66

1.42 (0.83-2.42)

1.06 (0.63-1.80)

Benzodiazepine dependence
(SDS score ≥7)
Risky alcohol consumption
(AUDIT-C score ≥5)

432

11

11

7

18

0.63 (0.25-1.57)

1.80 (0.89-3.61)

436

72

68

76

77

1.50 (0.86-2.60)

1.51 (0.85-2.68)

Used cannabis past month

436

65

61

66

79

1.26 (0.76-2.08)

2.36 (1.31-4.26)**

Used heroin past month

437

48

49

42

49

0.74 (0.45-1.20)

1.01 (0.62-1.67)

Used methamphetamine past
month

437

47

45

47

52

1.10 (0.68-1.77)

1.32 (0.80-2.17)

Injected any drug past month

436

85

85

82

90

0.83 (0.44-1.57)

1.66 (0.75-3.71)

Injected daily past month

436

34

38

27

27

0.59 (0.35-1.01)

0.60 (0.35-1.04)

Overdose past 12m

435

9

9

8

10

0.86 (0.36-2.07)

1.12 (0.48-2.60)

Used prescribed
benzodiazepine past month
Hospital visit past 12m (for any
health-related reason)
Seen GP past 12m (for any
health-related reason)

437

36

31

39

48

1.44 (0.87-2.36)

2.06 (1.24-3.42)**

433

10

10

9

14

0.90 (0.39-2.08)

1.46 (0.69-3.10)

433

72

71

65

80

0.76 (0.45-1.26)

1.62 (0.88-2.97)

Drug Use and Behaviours

Harms and Treatment

Note. Statistically significant values (p<.050) are bolded. (B) These outcomes were assessed in the Wave 1 interview; all other items were
assessed in Wave 3. PHQ-9: Patient Health Questionnaire; GAD-7: Generalized Anxiety Disorder 7-item scale; ICD10: International
Classification of Diseases version 10; SDS: Severity of Dependence Scale; AUDIT-C: Alcohol Use Disorders Identification Test-C; GP: general

practitioner; 12m: 12 months; M: median; IQR: interquartile range; RRR: relative risk ratio; 95%CI: 95% confidence interval.*p<.050;
**p<.010.

